Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Browse
Companies
Mundipharma International seeks products in analgesia, anesthesia and oncology to market through a pan-European sales force. More
BPL is one of the leading suppliers of plasma derived products in the global fractionation industry. BPL is a not-for-profit organization wholly owned by the UK government More
The University of Edinburgh has an international reputation for world-class research in medicine and biotechnology. More
LBN was established in June 2000, providing the first co-ordinated approach to biotechnology in London. With over 2000 members, LBN is now one of the largest biotechnology networks in Europe. More
LeadDiscovery offers intelligence services to the drug discovery sector. Focusing on pre-clinical research and analysis for identification and development of new therapeutic entities More
Genecom is the commercialisation arm of the Moredun Institute and the Institute for Animal Health. These institutes have international reputations in the area of animal health. More
ReGen is an early-stage biopharmaceutical company developing Colostrinin (a natural sourced material) for Alzheimers. Colostrinin may also have utility as a neutraceutical More
The IRC Network Biotechnology Thematic Group's goal is to contribute to the promotion of innovation in the European Biotechnology sector through technology transfer. More
QMUL aims to create social and economic benefits for society by developing a culture of innovation and enterprise that will facilitate the commercial exploitation of academic research and technology. More
Your selection
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us